Brought to you by 
CRO Patheon nets $570.5mm in IPO
26 Jul 2016
Executive Summary
Patheon NV (formerly Patheon Holdings Cooperatief UA) netted $570.5mm in its IPO through the sale of 29.5mm shares (including full exercise of the 4.5mm overallotment option shares) at $21 (midpoint of range). The selling stockholder also sold 4.8mm shares in the offering. The company's principal shareholders are private equity firm JLL Partners and Dutch science company Koninklijke DSM NV.
Deal Industry
- Contract Research, Toxicology Testing-CRO
- Pharmaceuticals
- Services
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
CRO Patheon nets $570.5mm in IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice